In hour-long, quarterly broadcasted industry-stakeholder discussions, P4A experts tackle complex subjects such as gene therapy and emerging technologies to help shape industry-wide conversations.
Gene Therapy is emerging as the new frontier of human medicine with the potential to cure hard-to-treat rare diseases. The human genome project’s conclusion in 2003 followed by the first gene therapy approval in Europe (2012) and the US (2017) were key milestones.
However, very little is known about this approach to treatment, creating myths and expectations.
The P4A webinar series uncovered such myths – from clinical evidence to commercial concerns – and put forth the readiness of key markets to adopt and integrate gene therapies.
We gained expert insights from a cross-section of stakeholders from the medical community, patients to industry and payers.